Chuanyong Wang, Qimou Li, Gangcheng Zhang, Zaixin Yu, Hongyan Tian, Caojin Zhang, Yucheng Chen, Yuhao Liu, Weifeng Wu, Xiulong Zhu, Xianyang Zhu, Huaru Hu, Jianguo He
Harnessing the strength of interpretable ML on detecting non-linear correlations, we developed a novel risk stratification model for unrepaired PAH-CHD, outperforming the ESC model. This tool assesses mortality risk regardless of Eisenmenger physiology, facilitating individualized clinical management.
BACKGROUND: Standard pulmonary arterial hypertension (PAH) risk models may not fully apply to PAH associated with unrepaired congenital heart disease (PAH-CHD). We aimed to develop and internally validate an interpretable machine learning (ML)-based risk model for adults with unrepaired PAH-CHD, comparing it against the recent European Society of Cardiology (ESC) model.
METHODS: Utilizing a nationwide prospective registry in China, we included adults with unrepaired PAH-CHD. Five survival models were trained and internally validated to predict all-cause mortality. The optimal model was interpreted via Shapley Additive exPlanations (SHAP) to identify the top 15 predictors and clinical cutoffs. Novel two-strata and continuous risk models were constructed; predictive accuracy was evaluated using the C-index and survival curves.
RESULTS: Among 601 patients (mean age 34; 56.4% Eisenmenger syndrome [ES]), 108 died during a median 76-month follow-up. The random survival forest model achieved the highest predictive performance (bootstrapping C-index 0.773). SHAP identified key predictors, including hemoglobin, body mass index, systolic blood pressure, and diastolic pulmonary artery pressure. The ESC two-strata model classified only 5.0% of patients as "Poorer prognosis" and failed to stratify the non-ES subgroup. The novel ML-derived risk model effectively stratified survival in both ES and non-ES cohorts (log-rank P < 0.001), outperforming the ESC model across all subgroups.
CONCLUSIONS: Harnessing the strength of interpretable ML on detecting non-linear correlations, we developed a novel risk stratification model for unrepaired PAH-CHD, outperforming the ESC model. This tool assesses mortality risk regardless of Eisenmenger physiology, facilitating individualized clinical management.